Commit Biologics appoints serial biotech founder as new CEO to take complement-powered immune engagers into the clinic
- Dr. Thomas L. F. Montgomery Andresen joins from T-Cypher Bio
- Follows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine release
- Commit is poised to nominate its first two clinical development candidates later in 2026
COPENHAGEN, Denmark — March 11, 2026 — Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in seed financing from Novo Holdings, Bioqube Ventures, and Korys, today announces the appointment of seasoned biotech entrepreneur Thomas L. F. Montgomery Andresen, PhD, as Chief Executive Officer. Dr. Andresen joins at a pivotal juncture to accelerate Commit’s transition into a clinical-stage company.
